1H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis
Open Access
- 3 May 2012
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 4 (1), 165-171
- https://doi.org/10.3892/etm.2012.567
Abstract
To identify the major serum biomarkers predicting the response to methotrexate (MTX) treatment in patients with early rheumatoid arthritis (RA), we evaluated the relationships between the individual response to MTX and various associated factors utilizing the 1H nuclear magnetic resonance (1H NMR)-based metabolomic method. Thirty-eight early RA patients were enrolled in this cohort study, and they received MTX (10 mg/week) orally as monotherapy for 24 weeks. According to the American College of Rheumatology criteria for improvement, clinical evaluation following MTX treatment was carried out at baseline and at the end of 24 weeks. Furthermore, collected serum samples were analyzed using 600 M 1H NMR for spectral binning. The obtained data were processed by both the unsupervised principal component analysis (PCA) and the supervised partial least squares discriminant analysis (PLS-DA). Lastly, multivariate analyses were performed to recognize the spectral pattern of endogenous metabolites related to MTX treatment. Differential clustering of 1H NMR spectra identified by PCA was found between the effective (n=25) and non-effective (n=13) group of RA patients receiving MTX treatment. Multivariate statistical analysis showed a difference in metabolic profiles between the two groups using PLS-DA (R2=0.802, Q2=0.643). In targeted profiling, 11 endogenous metabolites of the effective group showed a significant difference when compared with those of the non-effective group (p<0.05). Serum metabolites correlated with MTX treatment in patients with early RA were identified, which may be the major predictive factors for evaluating the response to MTX treatment in patients with early RA. Furthermore, our results highlight the usefulness of 1H NMR-based metabolomics as a feasible and efficient prognostic tool for predicting therapeutic efficacy to MTX treatment.Keywords
This publication has 28 references indexed in Scilit:
- NMR techniques in biomedical and pharmaceutical analysisJournal of Pharmaceutical and Biomedical Analysis, 2011
- Using NMR Metabolomics to Investigate Tricarboxylic Acid Cycle-dependent Signal Transduction in Staphylococcus epidermidisOnline Journal of Public Health Informatics, 2010
- Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic ReviewThe Journal of Rheumatology, 2010
- Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritisArthritis Research & Therapy, 2010
- Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic reviewThe Pharmacogenomics Journal, 2009
- Pattern Recognition Analysis for the Prediction of Adverse Effects by Nonsteroidal Anti-Inflammatory Drugs Using 1H NMR-Based Metabolomics in RatsAnalytical Chemistry, 2009
- Altered Metabolism of Growth Hormone Receptor Mutant Mice: A Combined NMR Metabonomics and Microarray StudyPLOS ONE, 2008
- Uric acid changes in urine and plasma: An effective tool in screening for purine inborn errors of metabolism and other pathological conditionsJournal of Inherited Metabolic Disease, 2007
- Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis & Rheumatism, 2004
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988